Wall Street's Top 10 Stock Calls This Week: Eli Lilly, DraftKings, United Airlines and More

16
1
Favorite

Wall Street's Top 10 Stock Calls This Week: Eli Lilly, DraftKings, United Airlines and More

thefly2023-08-13

What has Wall Street been buzzing about this week? Here are the top 5 Buy calls and the top 5 Sell calls made by Wall Street's best analysts during the week of August 7-11.Find all top-rated stocks by...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（1）

Ducky09
·2023-08-13
CVevV CC Z CC vceVvvc ezvCevc EvV
Reply
7
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1189898351?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-08-13 08:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1189898351","market":"us","top_or_hot":-1,"title":"Wall Street's Top 10 Stock Calls This Week: Eli Lilly, DraftKings, United Airlines and More","media":"thefly","content":"<div>\n<p>What has Wall Street been buzzing about this week? Here are the top 5 Buy calls and the top 5 Sell calls made by Wall Street's best analysts during the week of August 7-11.Find all top-rated stocks by...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3764686&headline=LLY;DKNG;UAL;MNST;W;WLK;NET;FTRE;AVIR;EGRX-BuySell-Wall-Streets-top--stock-calls-this-week&utm_source=https://thefly.com/&utm_medium=referral&utm_campaign=referral_traffic\">Source Link</a>\n\n</div>\n","source":"lsy1666364704704","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street's Top 10 Stock Calls This Week: Eli Lilly, DraftKings, United Airlines and More</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street's Top 10 Stock Calls This Week: Eli Lilly, DraftKings, United Airlines and More\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-08-13 08:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3764686&headline=LLY;DKNG;UAL;MNST;W;WLK;NET;FTRE;AVIR;EGRX-BuySell-Wall-Streets-top--stock-calls-this-week&utm_source=https://thefly.com/&utm_medium=referral&utm_campaign=referral_traffic><strong>thefly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What has Wall Street been buzzing about this week? Here are the top 5 Buy calls and the top 5 Sell calls made by Wall Street's best analysts during the week of August 7-11.Find all top-rated stocks by...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3764686&headline=LLY;DKNG;UAL;MNST;W;WLK;NET;FTRE;AVIR;EGRX-BuySell-Wall-Streets-top--stock-calls-this-week&utm_source=https://thefly.com/&utm_medium=referral&utm_campaign=referral_traffic\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NET","symbol_name":"Cloudflare, Inc.","start_time":0,"source_url":"https://thefly.com/landingPageNews.php?id=3764686&headline=LLY;DKNG;UAL;MNST;W;WLK;NET;FTRE;AVIR;EGRX-BuySell-Wall-Streets-top--stock-calls-this-week&utm_source=https://thefly.com/&utm_medium=referral&utm_campaign=referral_traffic","article_id":"1189898351","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1189898351","pubTimestamp":1691886776,"sourceInfo":{"source_id":"lsy1666364704704","name":"thefly"},"weMediaInfo":null,"summary":"What has Wall Street been buzzing about this week?","collect":0,"end_time":0,"defaultTopTitle":"thefly.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NET":"Cloudflare, Inc.","MNST":"怪物饮料","AVIR":"Atea Pharmaceuticals, Inc.","WLK":"Westlake Chemical Corp","DKNG":"DraftKings Inc.","LLY":"礼来","UAL":"联合大陆航空","W":"Wayfair","FTRE":"Fortrea Holdings Inc.","EGRX":"Eagle制药"},"translate_title":"华尔街本周十大股票电话会议：礼来公司、DraftKings、联合航空等","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVIR":1.1,"DKNG":1.1,"EGRX":1.1,"FTRE":1.1,"LLY":1.1,"MNST":1.1,"NET":1.1,"UAL":1.1,"W":1.1,"WLK":1.1},"content_text":"What has Wall Street been buzzing about this week? Here are the top 5 Buy calls and the top 5 Sell calls made by Wall Street's best analysts during the week of August 7-11.Find all top-rated stocks by the best-rated analysts on TipRanks.Top 5 Buy Calls:1. DraftKings upgraded to Overweight from Equal Weight at Wells FargoWells Fargo upgraded DraftKings (DKNG) to Overweight from Equal Weight with a price target of $37, up from $28. The company's earnings report showed that it is capturing market share, capitalizing on an improved product, and limiting operating expense growth, the firm tells investors in a research note. Wells sees upward EBITDA revisions to come and a path to $1B adjusted EBITDA in 2025 for DraftKings.Truist also upgraded DraftKings to Buy from Hold with a price target of $44, up from $31. The firm cites the company's inflection to profitability in Q2 as the management navigated around numerous early threats, and the path to \"significant and sustainable\" profitability has become clearer. DraftKings may be the \"best top-line story in gaming today\", even though the sector has been constrained by macro concerns, Truist adds.2. Eli Lilly upgraded to Buy from Hold at JefferiesJefferies upgraded Eli Lilly (LLY) to Buy from Hold with $615 price target, up from $408 prior. The firm cited the two recent positive GLP-1 data points, with SELECT trial exceeding the firm's base case and its Mounjaro sales exceeding consensus estimates by 28%. Jefferies is also boosting its Mounjaro peak sales view to $70B and its orforglipon view to $8.5B.3. Redburn more bullish on United Airlines, upgrades to BuyRedburn upgraded United Airlines (UAL) to Buy from Neutral with an $80 price target, citing its preference for international airlines and a more positive view on the impact of fewer narrow-body deliveries on both capex and growth over the coming years for the upgrade. Growing domestic capacity should continue to pressure unit revenue, the firm tells investors in a research note. Against this backdrop, Redburn reassessed its view on the U.S. airlines.4. Monster Beverage upgraded to Overweight at Piper SandlerPiper Sandler upgraded Monster Beverage (MNST) to Overweight from Neutral with a price target of $63, up from $60. The share pullback makes Monster's risk/reward more attractive, the firm tells investors in a research note. While the company's Q2 results were below expectations, there is nothing concerning about the business or its near- and long-term momentum, contends Piper. It remains bullish on the energy drink category specifically, especially with no private label presence, and expects Monster to continue to be well positioned.5. UBS upgrades Wayfair to Buy, raises price target to $110UBS upgraded Wayfair (W) to Buy from Neutral with a price target of $110, up from $72. The company's low valuation multiple does not fully price in its \"favorable intermediate term set-up,\" UBS tells investors in a research note. While sentiment on Wayfair shares has improved lately, the market will be surprised by the degree of profit upside the company is likely to generate in the coming periods, says the firm. It says the online retailer is \"just on the cusp\" of entering a multi-quarter period of sales growth and profit acceleration.Top 5 Sell Calls:1. Cloudflare downgraded to Sell at GuggenheimGuggenheim downgraded Cloudflare (NET) to Sell from Neutral with a $50 price target. The firm sees execution risk at Cloudflare and believes the stock \"has gotten way ahead of itself.\" There is risk in near, mid, and long-term estimates, and execution risk tied to the company's \"worthwhile, but aspirational goals,\" Guggenheimer tells investors in a research note. The firm says Cloudflare's \"modest\" Q2 beat will not likely carry over to the second half, where a \"steep hill\" of new annual recurring revenue \"needs to be climbed just to meet expectations.\"2. JPMorgan downgrades Westlake to Underweight, raises target to $123JPMorgan downgraded Westlake (WLK) to Underweight from Neutral with a price target of $123, up from $120. Westlake shares have outperformed the other deeper cyclical petrochemical companies since June, but Westlake does not offer the high free cash flow yield and large share repurchase capabilities of Olin nor does it offer the high 5%-plus dividend yields of Dow and Lyondell, the analyst tells investors in a research note. The firm expects Westlake's business conditions to continue to soften into the second half of 2023.3. BofA starts Labcorp spinoff Fortrea with an UnderperformBofA initiated coverage of Fortrea Holdings (FTRE) with an Underperform rating and $27 price target following its spinoff from Labcorp (LH) last month. The late-stage contract research organization, or CRO, is better as a standalone entity, but has underperformed peers historically and the firm doesn't see this changing quickly, BofA tells investors. A discount to peers is \"warranted at this time,\" the firm added.4. JPMorgan bearish on Atea Pharmaceuticals, downgrades to UnderweightJPMorgan downgraded Atea Pharmaceuticals (AVIR) to Underweight from Neutral without a price target. The firm says that despite reiterating on track clinical timelines for bemnifosbuvir, it remains skeptical of the value accretive potential of the product candidate in either indication. JPMorgan currently approved antivirals continuing to dominate a shrinking market opportunity as severe COVID case rates dwindle. The firm anticipates Atea shares continuing to be under pressure and underperforming.5. Piper downgrades Eagle Pharmaceuticals to Underweight on long-term concernsPiper Sandler downgraded Eagle Pharmaceuticals (EGRX) to Underweight from Neutral with a price target of $17, down from $26, following the company's Q2 report. Though the company having raised its FY20 adjusted EBITDA and EPS guidance \"is not lost on us,\" the firm says it \"continues to struggle\" with the longer-term EBITDA trajectory given what it views as \"challenging dynamics on multiple fronts,\" including declining contribution from bendamustine products and sluggish uptake of new products Barhemsys and Byfavo.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":208353264279680,"gmtCreate":1691891330697,"gmtModify":1691891335269,"author":{"id":"4106403626717070","authorId":"4106403626717070","name":"Ducky09","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"CVevV &nbsp;CC Z CC vceVvvc ezvCevc EvV","listText":"CVevV &nbsp;CC Z CC vceVvvc ezvCevc EvV","text":"CVevV CC Z CC vceVvvc ezvCevc EvV","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/208353264279680","repostId":1189898351,"repostType":2,"repost":{"id":"1189898351","pubTimestamp":1691886776,"share":"https://www.laohu8.com/m/news/1189898351?lang=&edition=full","pubTime":"2023-08-13 08:32","market":"us","language":"en","title":"Wall Street's Top 10 Stock Calls This Week: Eli Lilly, DraftKings, United Airlines and More","url":"https://stock-news.laohu8.com/highlight/detail?id=1189898351","media":"thefly","summary":"What has Wall Street been buzzing about this week?","content":"<html><head></head><body><p>What has Wall Street been buzzing about this week? Here are the top 5 Buy calls and the top 5 Sell calls made by Wall Street&#39;s best analysts during the week of August 7-11.<br/><br/>Find all top-rated stocks by the best-rated analysts on TipRanks.<br/><br/><strong><u>Top 5 Buy Calls:</u><br/></strong></p><p style=\"text-align: start;\"><strong>1. DraftKings upgraded to Overweight from Equal Weight at Wells Fargo</strong></p><p style=\"text-align: start;\">Wells Fargo upgraded DraftKings (DKNG) to Overweight from Equal Weight with a price target of $37, up from $28. The company&#39;s earnings report showed that it is capturing market share, capitalizing on an improved product, and limiting operating expense growth, the firm tells investors in a research note. Wells sees upward EBITDA revisions to come and a path to $1B adjusted EBITDA in 2025 for DraftKings.</p><p style=\"text-align: start;\">Truist also upgraded DraftKings to Buy from Hold with a price target of $44, up from $31. The firm cites the company&#39;s inflection to profitability in Q2 as the management navigated around numerous early threats, and the path to &#34;significant and sustainable&#34; profitability has become clearer. DraftKings may be the &#34;best top-line story in gaming today&#34;, even though the sector has been constrained by macro concerns, Truist adds.</p><p style=\"text-align: start;\"><strong>2. Eli Lilly upgraded to Buy from Hold at Jefferies</strong></p><p style=\"text-align: start;\">Jefferies upgraded Eli Lilly (LLY) to Buy from Hold with $615 price target, up from $408 prior. The firm cited the two recent positive GLP-1 data points, with SELECT trial exceeding the firm&#39;s base case and its Mounjaro sales exceeding consensus estimates by 28%. Jefferies is also boosting its Mounjaro peak sales view to $70B and its orforglipon view to $8.5B.</p><p style=\"text-align: start;\"><strong>3. Redburn more bullish on United Airlines, upgrades to Buy</strong></p><p style=\"text-align: start;\">Redburn upgraded United Airlines (UAL) to Buy from Neutral with an $80 price target, citing its preference for international airlines and a more positive view on the impact of fewer narrow-body deliveries on both capex and growth over the coming years for the upgrade. Growing domestic capacity should continue to pressure unit revenue, the firm tells investors in a research note. Against this backdrop, Redburn reassessed its view on the U.S. airlines.</p><p style=\"text-align: start;\"><strong>4. Monster Beverage upgraded to Overweight at Piper Sandler</strong></p><p style=\"text-align: start;\">Piper Sandler upgraded Monster Beverage (MNST) to Overweight from Neutral with a price target of $63, up from $60. The share pullback makes Monster&#39;s risk/reward more attractive, the firm tells investors in a research note. While the company&#39;s Q2 results were below expectations, there is nothing concerning about the business or its near- and long-term momentum, contends Piper. It remains bullish on the energy drink category specifically, especially with no private label presence, and expects Monster to continue to be well positioned.</p><p style=\"text-align: start;\"><strong>5. UBS upgrades Wayfair to Buy, raises price target to $110</strong></p><p style=\"text-align: start;\">UBS upgraded Wayfair (W) to Buy from Neutral with a price target of $110, up from $72. The company&#39;s low valuation multiple does not fully price in its &#34;favorable intermediate term set-up,&#34; UBS tells investors in a research note. While sentiment on Wayfair shares has improved lately, the market will be surprised by the degree of profit upside the company is likely to generate in the coming periods, says the firm. It says the online retailer is &#34;just on the cusp&#34; of entering a multi-quarter period of sales growth and profit acceleration.<br/><br/><strong>Top 5 Sell Calls:</strong></p><p style=\"text-align: start;\"><strong>1. Cloudflare downgraded to Sell at Guggenheim</strong></p><p style=\"text-align: start;\">Guggenheim downgraded Cloudflare (NET) to Sell from Neutral with a $50 price target. The firm sees execution risk at Cloudflare and believes the stock &#34;has gotten way ahead of itself.&#34; There is risk in near, mid, and long-term estimates, and execution risk tied to the company&#39;s &#34;worthwhile, but aspirational goals,&#34; Guggenheimer tells investors in a research note. The firm says Cloudflare&#39;s &#34;modest&#34; Q2 beat will not likely carry over to the second half, where a &#34;steep hill&#34; of new annual recurring revenue &#34;needs to be climbed just to meet expectations.&#34;</p><p style=\"text-align: start;\"><strong>2. JPMorgan downgrades Westlake to Underweight, raises target to $123</strong></p><p style=\"text-align: start;\">JPMorgan downgraded Westlake (WLK) to Underweight from Neutral with a price target of $123, up from $120. Westlake shares have outperformed the other deeper cyclical petrochemical companies since June, but Westlake does not offer the high free cash flow yield and large share repurchase capabilities of Olin nor does it offer the high 5%-plus dividend yields of Dow and Lyondell, the analyst tells investors in a research note. The firm expects Westlake&#39;s business conditions to continue to soften into the second half of 2023.</p><p style=\"text-align: start;\"><strong>3. BofA starts Labcorp spinoff Fortrea with an Underperform</strong></p><p style=\"text-align: start;\">BofA initiated coverage of Fortrea Holdings (FTRE) with an Underperform rating and $27 price target following its spinoff from Labcorp (LH) last month. The late-stage contract research organization, or CRO, is better as a standalone entity, but has underperformed peers historically and the firm doesn&#39;t see this changing quickly, BofA tells investors. A discount to peers is &#34;warranted at this time,&#34; the firm added.</p><p style=\"text-align: start;\"><strong>4. JPMorgan bearish on Atea Pharmaceuticals, downgrades to Underweight</strong></p><p style=\"text-align: start;\">JPMorgan downgraded Atea Pharmaceuticals (AVIR) to Underweight from Neutral without a price target. The firm says that despite reiterating on track clinical timelines for bemnifosbuvir, it remains skeptical of the value accretive potential of the product candidate in either indication. JPMorgan currently approved antivirals continuing to dominate a shrinking market opportunity as severe COVID case rates dwindle. The firm anticipates Atea shares continuing to be under pressure and underperforming.</p><p style=\"text-align: start;\"><strong>5. Piper downgrades Eagle Pharmaceuticals to Underweight on long-term concerns</strong></p><p style=\"text-align: start;\">Piper Sandler downgraded Eagle Pharmaceuticals (EGRX) to Underweight from Neutral with a price target of $17, down from $26, following the company&#39;s Q2 report. Though the company having raised its FY20 adjusted EBITDA and EPS guidance &#34;is not lost on us,&#34; the firm says it &#34;continues to struggle&#34; with the longer-term EBITDA trajectory given what it views as &#34;challenging dynamics on multiple fronts,&#34; including declining contribution from bendamustine products and sluggish uptake of new products Barhemsys and Byfavo.</p></body></html>","source":"lsy1666364704704","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street's Top 10 Stock Calls This Week: Eli Lilly, DraftKings, United Airlines and More</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street's Top 10 Stock Calls This Week: Eli Lilly, DraftKings, United Airlines and More\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-08-13 08:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3764686&headline=LLY;DKNG;UAL;MNST;W;WLK;NET;FTRE;AVIR;EGRX-BuySell-Wall-Streets-top--stock-calls-this-week&utm_source=https://thefly.com/&utm_medium=referral&utm_campaign=referral_traffic><strong>thefly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What has Wall Street been buzzing about this week? Here are the top 5 Buy calls and the top 5 Sell calls made by Wall Street's best analysts during the week of August 7-11.Find all top-rated stocks by...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3764686&headline=LLY;DKNG;UAL;MNST;W;WLK;NET;FTRE;AVIR;EGRX-BuySell-Wall-Streets-top--stock-calls-this-week&utm_source=https://thefly.com/&utm_medium=referral&utm_campaign=referral_traffic\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DKNG":"DraftKings Inc.","AVIR":"Atea Pharmaceuticals, Inc.","EGRX":"Eagle制药","FTRE":"Fortrea Holdings Inc.","LLY":"礼来","NET":"Cloudflare, Inc.","UAL":"联合大陆航空","MNST":"怪物饮料","WLK":"Westlake Chemical Corp","W":"Wayfair"},"source_url":"https://thefly.com/landingPageNews.php?id=3764686&headline=LLY;DKNG;UAL;MNST;W;WLK;NET;FTRE;AVIR;EGRX-BuySell-Wall-Streets-top--stock-calls-this-week&utm_source=https://thefly.com/&utm_medium=referral&utm_campaign=referral_traffic","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1189898351","content_text":"What has Wall Street been buzzing about this week? Here are the top 5 Buy calls and the top 5 Sell calls made by Wall Street's best analysts during the week of August 7-11.Find all top-rated stocks by the best-rated analysts on TipRanks.Top 5 Buy Calls:1. DraftKings upgraded to Overweight from Equal Weight at Wells FargoWells Fargo upgraded DraftKings (DKNG) to Overweight from Equal Weight with a price target of $37, up from $28. The company's earnings report showed that it is capturing market share, capitalizing on an improved product, and limiting operating expense growth, the firm tells investors in a research note. Wells sees upward EBITDA revisions to come and a path to $1B adjusted EBITDA in 2025 for DraftKings.Truist also upgraded DraftKings to Buy from Hold with a price target of $44, up from $31. The firm cites the company's inflection to profitability in Q2 as the management navigated around numerous early threats, and the path to \"significant and sustainable\" profitability has become clearer. DraftKings may be the \"best top-line story in gaming today\", even though the sector has been constrained by macro concerns, Truist adds.2. Eli Lilly upgraded to Buy from Hold at JefferiesJefferies upgraded Eli Lilly (LLY) to Buy from Hold with $615 price target, up from $408 prior. The firm cited the two recent positive GLP-1 data points, with SELECT trial exceeding the firm's base case and its Mounjaro sales exceeding consensus estimates by 28%. Jefferies is also boosting its Mounjaro peak sales view to $70B and its orforglipon view to $8.5B.3. Redburn more bullish on United Airlines, upgrades to BuyRedburn upgraded United Airlines (UAL) to Buy from Neutral with an $80 price target, citing its preference for international airlines and a more positive view on the impact of fewer narrow-body deliveries on both capex and growth over the coming years for the upgrade. Growing domestic capacity should continue to pressure unit revenue, the firm tells investors in a research note. Against this backdrop, Redburn reassessed its view on the U.S. airlines.4. Monster Beverage upgraded to Overweight at Piper SandlerPiper Sandler upgraded Monster Beverage (MNST) to Overweight from Neutral with a price target of $63, up from $60. The share pullback makes Monster's risk/reward more attractive, the firm tells investors in a research note. While the company's Q2 results were below expectations, there is nothing concerning about the business or its near- and long-term momentum, contends Piper. It remains bullish on the energy drink category specifically, especially with no private label presence, and expects Monster to continue to be well positioned.5. UBS upgrades Wayfair to Buy, raises price target to $110UBS upgraded Wayfair (W) to Buy from Neutral with a price target of $110, up from $72. The company's low valuation multiple does not fully price in its \"favorable intermediate term set-up,\" UBS tells investors in a research note. While sentiment on Wayfair shares has improved lately, the market will be surprised by the degree of profit upside the company is likely to generate in the coming periods, says the firm. It says the online retailer is \"just on the cusp\" of entering a multi-quarter period of sales growth and profit acceleration.Top 5 Sell Calls:1. Cloudflare downgraded to Sell at GuggenheimGuggenheim downgraded Cloudflare (NET) to Sell from Neutral with a $50 price target. The firm sees execution risk at Cloudflare and believes the stock \"has gotten way ahead of itself.\" There is risk in near, mid, and long-term estimates, and execution risk tied to the company's \"worthwhile, but aspirational goals,\" Guggenheimer tells investors in a research note. The firm says Cloudflare's \"modest\" Q2 beat will not likely carry over to the second half, where a \"steep hill\" of new annual recurring revenue \"needs to be climbed just to meet expectations.\"2. JPMorgan downgrades Westlake to Underweight, raises target to $123JPMorgan downgraded Westlake (WLK) to Underweight from Neutral with a price target of $123, up from $120. Westlake shares have outperformed the other deeper cyclical petrochemical companies since June, but Westlake does not offer the high free cash flow yield and large share repurchase capabilities of Olin nor does it offer the high 5%-plus dividend yields of Dow and Lyondell, the analyst tells investors in a research note. The firm expects Westlake's business conditions to continue to soften into the second half of 2023.3. BofA starts Labcorp spinoff Fortrea with an UnderperformBofA initiated coverage of Fortrea Holdings (FTRE) with an Underperform rating and $27 price target following its spinoff from Labcorp (LH) last month. The late-stage contract research organization, or CRO, is better as a standalone entity, but has underperformed peers historically and the firm doesn't see this changing quickly, BofA tells investors. A discount to peers is \"warranted at this time,\" the firm added.4. JPMorgan bearish on Atea Pharmaceuticals, downgrades to UnderweightJPMorgan downgraded Atea Pharmaceuticals (AVIR) to Underweight from Neutral without a price target. The firm says that despite reiterating on track clinical timelines for bemnifosbuvir, it remains skeptical of the value accretive potential of the product candidate in either indication. JPMorgan currently approved antivirals continuing to dominate a shrinking market opportunity as severe COVID case rates dwindle. The firm anticipates Atea shares continuing to be under pressure and underperforming.5. Piper downgrades Eagle Pharmaceuticals to Underweight on long-term concernsPiper Sandler downgraded Eagle Pharmaceuticals (EGRX) to Underweight from Neutral with a price target of $17, down from $26, following the company's Q2 report. Though the company having raised its FY20 adjusted EBITDA and EPS guidance \"is not lost on us,\" the firm says it \"continues to struggle\" with the longer-term EBITDA trajectory given what it views as \"challenging dynamics on multiple fronts,\" including declining contribution from bendamustine products and sluggish uptake of new products Barhemsys and Byfavo.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":16,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}